RECEIVED
CENTRAL FAX CENTER
AUG 31 2006

CLAIMS AMENDMENTS

1. (Currently Amended) A composition for ~~prevention~~ preventing and ~~treatment of~~treating oral cavity diseases, comprising:

a) ____a therapeutic agent which is soluble both in water and in alcohol;

b) ____~~in~~ a biocompatible polymeric material, ~~wherein~~ in which said therapeutic agent is admixed, said material comprising a liquid methacrylate copolymer in an alcoholic solution, wherein said material is substantially insoluble in water and is permeable to water ~~in case a film is formed topically~~

said agent and material being adapted to be spread topically forming a ~~solid~~ film through alcohol evaporation, said film being permeable to water and having said agent embedded therein, wherein an effective amount of said agent is released from said film over a period of a minimum 3 days up to 10 days~~soluble both in water and in alcohol, and that said biocompatible polymeric material is a liquid methacrylate copolymer EUDRAGIT® RL or EUDRAGIT® RS and mixtures thereof;~~

~~wherein a film is formed by spreading topically said composition and said therapeutic agent is released progressively by water permeation through said polymeric material~~.

2. (Cancelled)

3. (Cancelled)

4. (Original) The composition of claim 1, wherein the solvent of said liquid methacrylate copolymer is an alcoholic solvent that further comprises 1-20% water.

5. (Original) The composition of claim 1, wherein said therapeutic agent is selected from the group consisting of:

antibacterial agents--chlorexidine acetate, thimerosal, cetylpiridinio chloride, benzalkonium chloride, cetrimide, benzethonium chloride;

antibiotics--piperacillin sodium, carbenicillin sodium carindacillin sodium, chloramphenicol sodium succinate, clindamycin palmitate hydrochloride, cloxacillin sodium, erythromycin gluceptate and lactobionate, flucloxacillin sodium, lincomycin hydrochloride, nafcillin sodium, tetracycline hydrochloride, minociclyne;

dentinal desensitising agents--strontium chloride, zinc chloride, calcium chloride, magnesium chloride stannous chloride, potassium sorbate

antivirals--acyclovir, idoxouridine, amantadine, and mixtures thereof.

6. (Withdrawn) The composition of claim 1, wherein said biocompatible polymeric material and said therapeutic agent are mixed in the following weight ratio

Eudragit RL 100 0.3-5% (w/w)
Eudragit RS 100 0.5-10% (w/w)
Therapeutic agent 1-20% (w/w)
Ethanol 96% q.s. 100 g

7. (Withdrawn) The composition of claim 1, wherein said biocompatible polymeric material and said therapeutic agent are mixed in the following weight ratio

Eudragit RL 100 0.3-5% (w/w)
Eudragit RS 100 0.5-10% (w/w)
Therapeutic agent 1-20% (w/w)
Purified water 1-20% (w/w)
Ethanol 96% q.s. 100 g

8. (Currently Amended) The composition of claim 1, wherein said therapeutic agent is selected from the group consisting of: Piperacillin sodium, ~~Cholrampheniсol~~ chloramphenicol sodium succinate, and Clindamycin palmitate.

9. (Withdrawn) The composition of claim 1, wherein said biocompatible polymeric material and said therapeutic agent are mixed in the following weight ratio

Eudragit RL 100 0.3-5% (w/w)

Eudragit RS 100 0.5-10% (w/w)

Cetrimide 0.1-1%(w/w)

Chlorexidine acetate 0.05-0.5% (w/w)

Ethanol 96% q.s. 100 g

10. (Withdrawn) The composition of claim 1, wherein said biocompatible polymeric material therapeutic agents are mixed in the following weight ratio

Calcium chloride 1-15% (w/w)

Zinc chloride 1-15% (w/w)

Eudragit RS100 0.5-12% (w/w)

Ethanol 96% q.s. 100 g

wherein a second solution is added topically according to the following composition

Potassium fluoride 1-15% (w/w)

Dibasic potassium phosphate 1-20% (w/w)

Purified water q.s. 100 g is added topically for desensitisation of exposed dentin.

11. (Withdrawn) The composition of claim 1, wherein said biocompatible polymeric material therapeutic agents are mixed in the following weight ratio

Zinc chloride 1-10% (w/w)

Strontium chloride 1-10% (w/w)

Eudragit RS 100 0.5-12% (w/w)

Purified water 1-20% (w/w)

Ethanol 96% q.s. 100 g

wherein a second solution according to the following composition

Potassium fluoride 1-20% (w/w)

Purified water q.s. 100 g

is added topically for desensitisation of exposed dentin.

12. (Withdrawn) The composition of claim 1, for treating diseases caused by Herpes Labialis, wherein said biocompatible polymeric material and therapeutic agents are mixed in the following weight ratio Acyclovir 1-5% (w/w) Eudragit RL100 0.3-5%(w/w) Eudragit RS100 0.5-10% (w/w) Transcutol 1-15% (w/w) Ethanol 96% q.s. 100 g

13. (Withdrawn) A composition for the desensitisation of exposed dentin, comprising a therapeutic agent in a biocompatible polymeric material, wherein said biocompatible polymeric material is a liquid methacrylic polymer, said therapeutic agent is soluble both in water and in alcohol and is an alcoholic solution or an alcoholic gel of a zinc salt and a salt selected from the group consisting of calcium salt, a strontium salt, and a combination thereof, and said therapeutic agent in a biocompatible polymeric material being combined topically to an aqueous solution or an aqueous gel of potassium fluoride, with addition of dibasic potassium phosphate.

14. (New) A method of preventing and treating oral cavity diseases, comprising the steps of:

a) providing a therapeutic agent which is soluble both in water and in alcohol;

b) providing a biocompatible polymeric material comprising a liquid methacrylate copolymer in an alcoholic solution, wherein said material is insoluble in water and is permeable to water;

c) mixing said therapeutic agent and said polymeric material to form a mixture;

d) spreading said mixture topically forming a film through alcohol evaporation, said agent being embedded in said film, said film being insoluble in water and permeable to water;

e) allowing an effective amount of said agent to be released from said film by aqueous rinse through said film, said release lasting over a period of a minimum of 3 days and up to 10 days.